ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1422	National Cancer Institute	Html	en	Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood liver cancer.	unfavorable hepatoblastoma 0.444228 liver tumors 0.560678 recurrent hepatoblastoma 0.435695 pediatric hepatoblastoma 0.454465 ruptured hepatoblastoma 0.423384 metastatic hepatoblastoma 0.509586 probable hepatoblastoma 0.453029 Eur J Cancer 0.388707 international pediatric liver 0.386143 multiply relapsed hepatoblastoma 0.447121 children 0.485632 Hepatoblastoma clinical research 0.47139 standard-risk hepatoblastoma 0.42407 clinical trials 0.40571 apparently sporadic hepatoblastoma 0.4599 weight hepatoblastoma cases 0.474502 Hepatoblastoma state 0.437405 International Society 0.406829 PRETEXT group assignment 0.412995 pediatric liver 0.555337 small cell hepatoblastoma 0.447198 pediatric liver tumors 0.460989 childhood hepatoblastoma 0.480002 pediatric liver resection 0.388074 familial adenomatous polyposis 0.407751	et al. 0.704223 congenital hepatoblastoma 0.4367 unresectable hepatoblastoma cases 0.452922 surgical resection 0.477903 PUBMED Abstract 0.546371 Pediatr Blood Cancer 0.795718 paediatric hepatoblastoma 0.439301 pediatric liver tumor 0.53573 advanced hepatoblastoma 0.46193 childhood liver cancer 0.393775 Liver Tumor Study 0.447606 newly diagnosed hepatoblastoma 0.454459 Pediatr Surg 0.416351 Abstract 0.708564 Pediatr Hematol Oncol 0.541505 Clin Oncol 0.519738 unresectable hepatoblastoma 0.472209 complete surgical resection 0.406131 hepatoblastoma 0.939626 high-risk hepatoblastoma 0.561704 childhood high-risk hepatoblastoma 0.538739 Oncology Liver Tumor 0.378181 hepatoblastoma patients 0.439703 Oncology Group 0.393362	CLICK HERE
1650	National Cancer Institute	Html	en	Selected Vegetables/Sun's Soup (PDQ®)–Patient Version	Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	treatment 0.620935 cancer treatment 0.517212 cancer prevention 0.486935 Complementary Therapies Editorial 0.534234 United States 0.494682 Well-designed clinical trials 0.477309 Drug Administration 0.522277 Cancer Information Specialist 0.498157 cancer cells 0.558873 Cancer Information Service 0.567973 PDQ cancer information 0.645069 Cancer Complementary 0.510973 PDQ Selected Vegetables/Sun 0.52487 Vegetables/Sun’s Soup 0.718967 CAM therapies 0.498393 Soup ingredients 0.49536 treatment clinical trials 0.493338 National Cancer Institute 0.676034 clinical trials 0.788657 alternative medicine 0.562862 standard food 0.487423 conventional treatment 0.48119 cancer information summary 0.571239 alternative cancer therapies 0.505071	Federal Trade Commission 0.49349 National Institutes 0.486354 clinical trial 0.532528 new treatment 0.541852 mung bean 0.494966 CAM cancer research 0.493212 breast cancer prevention 0.484457 shiitake mushroom 0.517658 patients 0.594168 cancer patients 0.547142 new treatment works 0.477537 Cancer Care page 0.486585 health 0.482953 Selected Vegetables/Sun 0.982781 PDQ summary 0.47773 non-small cell lung 0.519358 NCI PDQ cancer 0.530378 cancer information database 0.505237 cell lung cancer 0.547396 alternative therapies 0.532329 cancer information summaries 0.505491 Frozen Selected Vegetables 0.492972 Therapies Editorial Board 0.515019	CLICK HERE
1737	National Cancer Institute	Html	en	Lasers in Cancer Treatment	A fact sheet that describes use of high-intensity light in cancer treatment, its advantages and disadvantages, and types of procedures that use it.	cancer treatment 0.596049 flexible endoscope 0.380536 health care provider 0.409067 body 0.411001 argon lasers 0.532774 high-intensity light 0.445412 clinical trials 0.451803 bright indoor light 0.427495 LITT 0.389656 Laser-induced interstitial thermotherapy 0.422778 seal lymph vessels 0.416005 specific wavelength 0.3683 lower risk 0.371973 laser light 0.694799 normal tissue 0.366241 clinical trials page 0.408776 Ordinary light 0.384552 radiation therapy 0.382841 powerful beam 0.363945 NCI fact sheet 0.529266 light bulb 0.385224 sheet Photodynamic Therapy 0.436155 standard surgical tools 0.542942 photodynamic therapy 0.436739 early stages 0.365543	optical fibers 0.421684 fact sheet Hyperthermia 0.42197 cancer cells 0.463993 colon polyps 0.373762 cell skin cancer 0.441978 Cancer Information Service 0.427676 interstitial laser photocoagulation 0.453094 lasers 0.686527 strict safety precautions 0.41161 precancerous growths 0.534102 light amplification 0.39079 laser surgery 0.440343 patient 0.366006 tumor cells 0.428295 PDT 0.367707 nerve endings 0.364934 precise surgical work 0.423122 superficial cancers 0.447776 YAG laser light 0.46252 laser therapy 0.900564 tumors 0.382431 cell lung cancer 0.440229 tiny areas 0.365703 narrow beam 0.364464	CLICK HERE
1806	National Cancer Institute	Html	es	Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.	after d2 gastrectomy 0.313513 gastrectomía d2 0.31496 Cunningham D 0.34388 Macdonald JS 0.318723 Chemoradiotherapy after surgery 0.344328 randomised controlled 0.319618 combined modality therapy 0.360634 mejoría significativa 0.31176 Stenning SP 0.310838 intergroup trial calgb 0.31542 Postoperative adjuvant chemoradiation 0.322032 after ci 5-fu 0.317294 fase iii 0.364462 Estados Unidos 0.347269 with s-1 0.314235 randomized trial comparing 0.314288 quimiorradioterapia posoperatoria 0.360835 ensayo rtog-9904 0.324678 patients with 0.484752 adyuvante versus tasa 0.360686 supportive care 0.325372 Clinical Oncology 0.311085 Perioperative chemotherapy versus 0.334581 chemotherapy plus best 0.312401 Smalley SR 0.318682	with surgery 0.339493 Ajani JA 0.354002 or gastroesophageal junction 0.340588 ensayo swog-s0425 0.324881 Allum WH 0.311046 quimiorradioterapia adyuvante versus 0.364135 estadio ib 0.338006 gastrectomía curativa d2 0.319296 Van Cutsem E 0.313883 Benedetti J 0.318647 quimioterapia perioperatoria 0.352185 gastric carcinoma 0.325701 gastric cancer 0.935626 Clin Oncol 0.612714 or gastro-oesophageal junction 0.317111 trial comparing 0.314461 supportive care with 0.324232 Winter K 0.319459 Gastric Cancer Study 0.317632 chemotherapy versus surgery 0.338116 grupo s-1 0.317965 Okawara GS 0.319919 care with best 0.314996 quimioterapia posoperatoria 0.31518	CLICK HERE
1992	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil.	tumores smarcb1 0.603767 células madre 0.629225 efectos secundarios meses 0.607017 siguientes aspectos 0.601615 siguientes especialistas 0.601426 genes smarcb1 0.609598 PDQ Descripción 0.60415 efectos tardíos 0.611777 PDQ Tumores 0.606157 PDQ Efectos tardíos 0.604371 National Cancer Institute 0.601403 siguientes riesgos 0.600917 profesional entrenado 0.601618 Instituto Nacional 0.6024 PDQ Tratamiento 0.603883	presente sumario 0.602507 determinados cambios 0.601063 presente sección 0.601013 nuevos tipos 0.601364 sistema nervioso central 0.98418 Physician Data Query 0.604988 brain tumor 0.602951 Aboutâ„¢ Brain Tumors 0.601752 ensayos clínicos.Terapia 0.60282 siguientes terapias 0.601133 siguientes enlaces 0.601027 Brain Tumor Consortium 0.605055 panel derecho 0.601581 siguientes trastornos 0.601436	CLICK HERE
2051	National Cancer Institute	Html	es	Vacunas contra el cáncer	Hoja informativa que define los tipos de vacunas y explica cómo funcionan, cómo se preparan, y describe la investigación relacionada con su uso.	stemness-related tumor 0.305626 Mortality Weekly Report 0.305127 cancer vaccines 0.384507 células t 0.36244 células apc 0.361199 immune system 0.308685 proteína llamada factor 0.306202 vacunas protegen 0.338385 promising treatment modality 0.305201 beyond current paradigms 0.30561 hepatitis b 0.31173 Estados Unidos 0.331683 Expert Opinion 0.310074 fuerte respuesta 0.312982 Sipuleucel-T immunotherapy 0.305397 PubMed Abstract 0.971511 fuertes respuestas 0.305062 tumor antigen discovery 0.307826 proteína llamada 0.309122 vacunas autólogas 0.332195 invasores foráneos 0.325813 papiloma humano tipos 0.309997 Therapeutic vaccines as 0.30821 British Medical Journal 0.305786 therapy through immunomodulation 0.306217	frecuencia citocinas 0.305145 Schlom J 0.308012 suficientes antígenos 0.322846 factor estimulador 0.309823 programmed cell death 0.30504 inmunitario llamadas células 0.349485 moving beyond current 0.316247 comprehensive immunization strategy 0.30562 vacunas alogénicas 0.333841 cabo respuestas 0.305615 Reviews Cancer 0.310845 Mutant MHC class 0.305006 TRICOM vector based 0.304939 stable metastatic breast 0.304849 Current Pharmaceutical Design 0.305726 Therapeutic Advances 0.304747 cuello uterino 0.354099 mutational neoepitopes reveals 0.305636 tumor model 0.304956 Clinical Cancer Research 0.341107 Gulley JL 0.308772 vacunas resultantes 0.336516 New England Journal 0.315061 células renales 0.33154	CLICK HERE
2052	National Cancer Institute	Html	es	Terapias biológicas para el cáncer	Hoja informativa sobre la función del sistema inmunitario; describe la acción de las terapias biológicas.	Haluska FG 0.420038 Redig AJ 0.419038 ARN mensajero 0.423865 killer cell-based immunotherapy 0.432963 células hijas 0.643617 Canese P 0.41842 O'Day SJ 0.419485 clinical applications 0.420154 we tilt 0.419245 immune system 0.418755 altas dosis 0.418691 linfocitos b 0.794775 antígeno cd52 0.453352 Translational Medicine 0.419593 Comité Asesor 0.418458 biological therapy 0.455134 Internal Medicine 0.419677 Estados Unidos 0.448833 Expert Opinion 0.421046 linfocitos t 0.82421 intrusos foráneos 0.428976 towards immune-mediated 0.419994 PubMed Abstract 0.779921 metastatic melanoma 0.424461 madre sanas formadoras 0.440701	terapia modificadora 0.491313 Abeloff's Clinical Oncology 0.43296 mARN blanco 0.422446 antígeno cd20 0.515911 bacteria bacilo 0.445994 Improved survival with 0.436486 invasores foráneos 0.480692 células madre 0.955075 molécula her-2 0.428705 Cancer immunology 0.420503 Ningún virus 0.447968 on tumor immunology 0.437409 McDermott DF 0.418981 envoltorio protector 0.421713 IFN)-dependent activation 0.420375 terapia biológica usa 0.634008 90Y‑ibritumomab tiuxetán 0.424391 ingeniería genética 0.421138 sistema inmunitario.  aún 0.450887 escasa toxicidad 0.422699 biológica usa organismos 0.547748 Aún más 0.468819 virus vector 0.444624 New England Journal 0.430623	CLICK HERE
3935	National Cancer Institute	Html	es	Cáncer recurrente: cáncer que regresa	El cáncer puede regresar cuando el tratamiento no elimina o destruye por completo todas las células cancerosas. Aprenda acerca de los diferentes tipos de recurrencia -recidiva- y cómo se vuelve a asignar un estadio al cáncer y se da tratamiento.			CLICK HERE
14601	National Cancer Institute	Html	en	Childhood Vascular Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood vascular tumors.	lesions 0.459907 body 0.444762 PDQ cancer information 0.428885 steroid therapy 0.431929 malignant tumors 0.409372 clinical trials 0.622735 aggressive vascular tumors 0.43708 congenital hemangioma 0.425723 cancer information summary 0.40263 Diagnostic Tests 0.677407 liver 0.469914 lobular capillary hemangioma 0.410892 blood vessels 0.494734 pyogenic granuloma 0.401485 diffuse tumors 0.399482 benign vascular tumor 0.531292 vascular tumors 0.851122 clinical trial 0.485314 spindle cell hemangiomas 0.4591 malignant vascular tumors 0.461238 radiation therapy 0.585507 following 0.416254 late effects 0.40785 General Information section 0.953371	treatment 0.883924 blood vessel 0.40513 childhood vascular tumor 0.423751 skin 0.519128 vascular tumor 0.671886 benign vascular tumors 0.586046 infantile hemangiomas 0.495631 signs 0.415044 treatment clinical trials 0.412572 procedures 0.39986 multiple lesions 0.412762 tumor cells 0.435841 new treatment 0.424941 topical beta-blocker therapy 0.421578 kaposiform hemangioendothelioma 0.442163 hemangiomas 0.524006 risk factor 0.415027 childhood vascular tumors 0.50237 benign tumors 0.412061 blood vessel tumors 0.39943 kaposi sarcoma 0.437901 standard treatment 0.431582 diffuse liver tumors 0.410968 surgery 0.449251	CLICK HERE
16846	National Cancer Institute	Html	en	The University of Texas MD Anderson Cancer Center—Targeted Therapeutics for Ovarian Cancer and its Microenvironment – Treatment and Theoretical Modeling	Will offer nanotherapeutic formulations and novel approaches targeting multiple components of the tumor and its microenvironment, specifically for high-grade serous ovarian cancers.	Anil Sood 0.374281 critical molecular targets 0.456713 significant role 0.350306 ovarian cancer models 0.573698 Gabriel Lopez-Berestein 0.357257 monocyte-macrophage axis 0.343069 dual effect nanoparticles 0.489182 tumor-associated macrophages 0.355321 tumor microenvironment interactions 0.655973 significant antitumor activity 0.470227 five-year mortality rates 0.488005 AXL aptamers 0.532934 AXL-receptor binding aptamers 0.494135 specific AXL aptamers 0.512408 eventual tumor growth 0.616726 ovarian cancer 0.98899 gene silencing molecules 0.467313 current regimens 0.384525 Lokesh sRao 0.372622 Principal Investigators 0.351287 therapeutic nanoparticles 0.389578 maximal anti-tumor efficacy 0.546141 tumor progression 0.503786 Vittorio Cristini 0.380084 therapeutic efficacy 0.513726	Zhihui Wang 0.359239 nanoparticle surface 0.346896 nanoparticle effects 0.34271 drug resistance 0.343585 Sunila Pradeep 0.383374 tumor-promoting TAMs 0.351562 slow-release dual assembly 0.461875 MMA cell accumulation 0.438136 particularly attractive approach 0.453092 deadliest gynecological cancer 0.510101 tumor growth 0.640954 tumor cells 0.528853 David Volk 0.359179 platinum/taxane-based regimens 0.397302 optimal dosing regimens 0.492748 efficacy profiles 0.393175 high mortality rates 0.477298 multipronged dosing schedules 0.45156 Bulent Ozpolat 0.372014 slow release DANPs 0.440473 Traditional therapy 0.34917 serous ovarian cancer 0.612409 cancer biology 0.356075 tumor microenvironment 0.813294	CLICK HERE